Potential of Bacteriophage Therapy in Treating Antibiotic-Resistant Infections

DOI: https://doi.org/10.63345/ijrmp.v12.i8.2

Anika Dey

Independent Researcher

West Bengal, India

Abstract

Antibiotic resistance has emerged as a formidable challenge in modern medicine, rendering conventional therapies less effective and prompting the urgent search for alternatives. Bacteriophage therapy, the use of viruses that infect and lyse bacteria, has re‐gained attention as a potential solution for combating multidrug‐resistant infections. This manuscript reviews the current state of bacteriophage therapy, highlights its mechanisms of action, and examines clinical and preclinical studies up to 2022. We discuss advances in bacteriophage isolation, engineering, and delivery, as well as obstacles such as regulatory challenges and potential immunogenicity. A statistical analysis of recent clinical data is presented, and the methodology for experimental evaluation is described. Our findings suggest that, with optimized protocols and targeted selection, bacteriophage therapy may serve as a complementary or alternative treatment for infections unresponsive to antibiotics. Further research and controlled clinical trials are warranted to confirm efficacy, safety, and the best practices for implementation.

Keywords

Bacteriophage therapy; Antibiotic resistance; Multidrug-resistant infections; Phage engineering; Clinical trials.

References

• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.explorationpub.com%2FJournals%2Fem%2FArticle%2F1001217&psig=AOvVaw00DXTJVgUXTzvUAjXgBNvN&ust=1742128596499000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCJj_xf6MjIwDFQAAAAAdAAAAABAX
• https://www.google.com/url?sa=i&url=https%3A%2F%2Fhealthify.nz%2Fmedicines-a-z%2Fa%2Fantibiotic-resistance%2F&psig=AOvVaw0fgd2Qj0JSnUrTp4xzvDA7&ust=1742135997175000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCNChpMKojIwDFQAAAAAdAAAAABAS
• Abedon, S. T. (2011). Phage therapy: Eco-logical and therapeutic perspectives. Bacteriophage, 1(2), 137–143.
• Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future Microbiology, 8(6), 769–783.
• Doss, J., Culbertson, K., Hahn, D., Camacho, J., & Barekzi, N. (2017). A review of phage therapy against bacterial infections. Critical Reviews in Microbiology, 43(5), 647–657.
• Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host & Microbe, 25(2), 182–193.
• Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. T. (2010). Phage therapy in the 21st century: Current challenges and future prospects. Therapeutic Advances in Infectious Disease, 6(1), 63–84.
• Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001). Bacteriophage therapy. Antimicrobial Agents and Chemotherapy, 45(3), 649–659.
• Chan, B. K., & Abedon, S. T. (2012). Phage therapy pharmacology: Phage cocktails, dynamics, and biofilm disruption. Antimicrobial Agents and Chemotherapy, 56(3), 100–108.
• Górski, A., et al. (2019). Perspectives of phage therapy in infectious diseases: Challenges and opportunities. Antibiotics, 8(3), 131.
• Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., … & Strathdee, S. A. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 61(10), e01070-17.
• Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009). Bacteriophage therapy for respiratory infections: A review. Respiratory Research, 10, 82.
• Pirnay, J.-P., De Vos, D., Verbeken, G., Rose, T., Glonti, T., Tabernero, L., … & Lavigne, R. (2018). Quality-controlled production of therapeutic bacteriophages. Pharmaceutical Research, 35, 158.
• Oechslin, F. (2018). Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses, 10(4), 207.
• Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2016). Phage-mediated killing of bacterial biofilms. PLOS ONE, 11(9), e0162860.
• Wright, A., et al. (2020). Clinical application of bacteriophage therapy: Recent trends and future directions. Frontiers in Microbiology, 11, 990.
• Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., … & Debarbieux, L. (2010). Bacteriophage therapy: From in vitro to in vivo. Virology Journal, 7, 81.
• Malik, D. J., et al. (2017). Bacteriophage therapy in clinical practice: Challenges and perspectives. Expert Review of Anti-infective Therapy, 15(5), 459–466.
• Dąbrowska, K., & Abedon, S. T. (2019). Pharmacologically informed phage therapy: Pharmacokinetics and pharmacodynamics. Viruses, 11(2), 191.
• McCallin, S., et al. (2019). Bacteriophage treatment of Pseudomonas aeruginosa infections: A review of clinical and preclinical data. Journal of Applied Microbiology, 127(5), 1248–1261.
• Cooper, C., et al. (2020). The promise of bacteriophage therapy for multidrug-resistant infections: Current status and future directions. Journal of Infectious Diseases, 221(8), 1203–1210.
• Pires, D. P., et al. (2021). Engineering phages to combat antibiotic-resistant bacteria: Advances and perspectives. Trends in Biotechnology, 39(10), 1075–1087.